文献速递生殖医学妇科

单基因病植入前遗传学检测不良预后参数研究

Parameters of poor prognosis in preimplantation genetic testing for monogenic disorders.
PubMed 文献 · Hum Reprod · 2021-01-01

该单中心回顾性队列研究纳入2011至2015年2265个PGT-M周期与2833个常规ICSI周期,比较累积活产率(CLBR)及影响因素。PGT-M组CLBR较低(29.4% vs 35.0%),女性年龄、既往ART周期数、获卵数和促性腺激素剂量显著影响CLBR;≤40岁女性获卵数≥7时预测CLBR≥10%,获卵数≥3时≥5%。

要点

  • PGT-M单周期CLBR受女性年龄、既往ART周期数、获卵数和促性腺激素剂量显著影响。
  • ≤40岁女性获卵数≥7时预测CLBR至少10%,获卵数≥3时至少5%。
  • 每周期至少2枚获卵或1枚可移植胚胎可使预测CLBR超过10%。

核心结论

  • PGT-M单周期CLBR受女性年龄、既往ART周期数、获卵数及促性腺激素剂量显著影响。
  • ≤40岁女性获卵数≥7时预测CLBR≥10%,获卵数≥3时≥5%。

研究设计与样本

  • PGT-M采用卵裂球活检DNA多重短串联重复序列(STR)标记。
  • 多因素回归分析校正女性年龄、既往ART周期数、获卵数/可移植胚胎数及促性腺激素剂量。

主要发现

  • PGT-M组女性年龄32.0岁 vs 34.5岁,既往ART周期数1.1 vs 0.9,促性腺激素剂量2367 vs 1984 IU。
  • PGT-M组每周期获卵数11.8 vs 8.3,可移植胚胎数1.7 vs 2.8,CLBR 29.4% vs 35.0%。
  • 两组预测CLBR均随获卵数和可移植胚胎数增加而升高。
  • 每PGT-M周期至少2枚获卵或1枚胚胎可使估计CLBR超过10%。
  • ≤40岁女性获卵数≥7时预测CLBR≥10%(范围10-30%),获卵数≥3时≥5%(范围5-17%)。

关键数值与推荐

  • ≤40岁女性获卵数≥7时单周期预测CLBR≥10%(范围10-30%)。
  • ≤40岁女性获卵数≥3时单周期预测CLBR≥5%(范围5-17%)。
  • 每PGT-M周期至少2枚获卵或1枚可移植胚胎可使估计CLBR超过10%。

临床怎么用

  • 可利用本研究预测CLBR表为PGT-M夫妇提供更具体的预后咨询以辅助生殖决策。
  • 当治疗可能无效时,应基于女性年龄和获卵数向夫妇明确告知预后。

局限性

  • 尽管样本量大,但混杂因素校正有限且缺乏特定PGT-M对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the likelihood of success of a single cycle of preimplantation genetic testing for monogenic disorders (PGT-M), measured as the cumulative live birth rate (CLBR) and based on various patient demographics? SUMMARY ANSWER: For all women aged ≤40 years, the CLBR was at least 10% when the number of oocytes was ≥7 (range 10-30%) or was at least 5% when the number of oocytes was ≥3 (range 5-17%). WHAT IS KNOWN ALREADY: The number of oocytes is significantly associated with the number of embryos for genetic testing and the clinical outcome in PGT-M. Embryos diagnosed as affected or embryos that remain without diagnosis cannot be used for embryo transfer. The size of the group of embryos non-suitable for transfer varies between 25% and 81%, depending on the indication. Thus, PGT-M is more likely to be more severely impacted by suboptimal ovarian response, poor fertilization and suboptimal embryo development than conventional IVF/ICSI schemes without PGT. STUDY DESIGN, SIZE, DURATION: This was a single-centre retrospective comparative cohort study, of cycles between January 2011 and December 2015. A total number of 2265 PGT-M cycles were compared to 2833 conventional ICSI cycles. The principal aim of our study was the identification of the parameters of poor CLBR in couples undergoing PGT-M using multiplex short tandem repeat (STR) markers on blastomere biopsy DNA. The secondary aim was to compare the parameters of poor CLBR of the PGT-M population to those of couples undergoing ICSI without PGT. PARTICIPANTS/MATERIALS, SETTING, METHODS: The baseline characteristics of the PGT-M group were compared to the conventional ICSI group. A multiple regression analysis was applied to account for the following potential confounding factors: female age, number of previous ART cycles, number of oocytes/suitable embryos for transfer and dosage of gonadotrophins used for ovarian stimulation. MAIN RESULTS AND THE ROLE OF CHANCE: The PGT-M group was younger (female age 32.0 vs 34.5 years), had a higher number of previous ART cycles (1.1 vs 0.9 cycles) and used more gonadotrophins (2367 vs 1984 IU). Per cycle, the PGT-M group had more retrieved oocytes (11.8 vs 8.3 oocytes), fewer suitable embryos for transfer (1.7 vs 2.8 embryos) and a lower CLBR (29.4% vs 35.0%). Multiple regression analysis showed that the CLBR in the PGT-M group was significantly influenced by female age, the number of previous ART cycles, the number of oocytes and the dose of ovarian stimulation. In both groups, the predicted CLBR increased with increasing numbers of oocytes and suitable embryos. At least two retrieved oocytes or one embryo per single PGT-M cycle could confer an estimated CLBR above 10%. By assessing female age and the number of retrieved oocytes together, it was shown that for all women aged ≤40 years, the predicted CLBR per single PGT-M cycle was ≥10% when the number of oocytes was ≥7 or was ≥5% when the number of oocytes was ≥3. LIMITATIONS, REASONS FOR CAUTION: Despite the large sample size, the findings are confined by limited confounder adjustment and the lack of specific PGT-M comparators. WIDER IMPLICATIONS OF THE FINDINGS: This study aimed to describe the likelihood of success of PGT-M treatment, measured as CLBR, based on various patient demographics. In a PGT-M program, couples need to be informed of the prognosis more specifically when it is futile. The table of predicted CLBRs presented in this study is a useful tool in counselling PGT-M couples for making reproductive choices. STUDY FUNDING/COMPETING INTEREST(S): No funding was required and there are no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Van Der Kelen A, Santos-Ribeiro S, De Vos A, et al. Parameters of poor prognosis in preimplantation genetic testing for monogenic disorders. Hum Reprod. 2021. PMID: 34142115. doi:10.1093/humrep/deab136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。